EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

Lucía Sánchez-Peña iD, Salud Rodríguez-Pallares iD, Pablo Aja-Macaya iD, Tania Blanco-Martín iD, Lucía González-Pinto iD, Gloria Pérez-Rodríguez iD, Christophe Le Terrier iD, Inés Portillo-Calderón iD, Esther Recacha iD, Cristina Riazzo iD, Juan Carlos Vázquez-Ucha iD, Alejandro Beceiro iD und 6 weitere

Antimicrobial Agents and Chemotherapy · 03.09.2025 · 69 (9)

DOI: 10.1128/aac.00533-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.09.2025. Verfasst von Lucía Sánchez-Peña und 17 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Sp…. Hauptthemen laut MEDLINE: Meropenem, beta-Lactamases, beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Axencia Galega de Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meropenembeta-Lactamasesbeta-Lactamase InhibitorsAnti-Bacterial AgentsBacterial ProteinsEnterobacteriaceaeMicrobial Sensitivity TestsEscherichia coliHumansAzabicyclo CompoundsBoronic AcidsCarbapenem-Resistant Enterobacteriaceaebeta-Lactams

Stichwörter der Autor:innen

Enterobacteralesbeta-lactambeta-lactamasebeta-lactamase inhibitorcarbapenemasecarbapenemase-producing Enterobacteralesxeruborbactam

Substanzen

Meropenembeta-Lactamasesbeta-Lactamase InhibitorsAnti-Bacterial AgentscarbapenemaseBacterial ProteinsAzabicyclo CompoundsBoronic Acidsbeta-Lactams

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • CIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
  • Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive Care, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Laboratorio de Referencia para Tipado Molecular y Detección de Mecanismos de Resistencia a Antimicrobianos de Andalucía (PIRASOA), Unidad de Gestión Clínica de Microbiología y Enfermedades Infecciosas, Hospital Universi…

ORCID-Profile: Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, Tania Blanco-Martín, Lucía González-Pinto, Gloria Pérez-Rodríguez, Christophe Le Terrier, Inés Portillo-Calderón, Esther Recacha, Cristina Riazzo, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Belén Aracil, Laurent Poirel, Germán Bou, Jorge Arca-Suárez

Förderung

  • Instituto de Salud Carlos III
  • Axencia Galega de Innovación

Zitieren

APA

Sánchez-Peña, L., Rodríguez-Pallares, S., Aja-Macaya, P., Blanco-Martín, T., González-Pinto, L., Pérez-Rodríguez, G., Le Terrier, C., Portillo-Calderón, I., Recacha, E., Riazzo, C., Vázquez-Ucha, J. C., Beceiro, A., Aracil, B., Oteo-Iglesias, J., Martínez-Martínez, L., Poirel, L., Bou, G., & Arca-Suárez, J. (2025). Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. Antimicrobial Agents and Chemotherapy, 69(9). https://doi.org/10.1128/aac.00533-25

Vancouver

Sánchez-Peña L, Rodríguez-Pallares S, Aja-Macaya P, Blanco-Martín T, González-Pinto L, Pérez-Rodríguez G, et al. Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. Antimicrobial Agents and Chemotherapy. 2025;69(9). doi:10.1128/aac.00533-25

BibTeX
@article{SnchezPea2025,
  author = {Sánchez-Peña, Lucía and Rodríguez-Pallares, Salud and Aja-Macaya, Pablo and Blanco-Martín, Tania and González-Pinto, Lucía and Pérez-Rodríguez, Gloria and Le Terrier, Christophe and Portillo-Calderón, Inés and Recacha, Esther and Riazzo, Cristina and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Aracil, Belén and Oteo-Iglesias, Jesús and Martínez-Martínez, Luis and Poirel, Laurent and Bou, Germán and Arca-Suárez, Jorge},
  title = {Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {9},
  doi = {10.1128/aac.00533-25}
}
Kostenlos starten →